Mylan Ducks $15M Bristol-Myers Contract Suit Over HIV Drug

Law360, New York (August 12, 2013, 5:17 PM EDT) -- Mylan Inc. on Monday dodged a $15 million breach of contract suit from Bristol-Myers Squibb Co. after a New York federal judge found that an agreement between the companies didn’t bar Mylan’s sales of an HIV drug in Venezuela, although a patent infringement complaint is still possible.

The opinion from U.S. District Judge Paul A. Engelmayer turned on a highly technical reading of a contract that immunized Mylan from patent infringement liability when selling a generic version of Reyataz, or atazanavir, in India and sub-Saharan Africa....
To view the full article, register now.